Risky business: Target choice in adoptive cell therapy

Blood

Volumn 122, Issue 20, 2013, Pages 3392-3394

  Morgan, Richard A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIVATUZUMAB; CD44V6 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 3;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE CELL THERAPY; AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; CELL THERAPY; CELL TRANSFER; GLIOBLASTOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 84888242742     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-527622     Document Type: Review

References (8)

1. Casucci M, Nicolis Di Robilant B, Falcone L, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood. 2013;122(20):3461-3472.
2. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
3. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.
4. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709-2720.
5. Li G, Wong AJ. EGF receptor variant III as a target antigen for tumor immunotherapy. Expert Rev Vaccines. 2008;7(7):977-985.
6. Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747-752.
7. Caballero OL, Chen YT. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 2009;100(11):2014-2021.
8. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917-924.